There are now three US FDA approved CDK4/6 inhibitors for breast cancer, Palbociclib (IBRANCE®, Pfizer Inc.), ribociclib (Kisqali®, Novartis Pharmaceuticals Corporation), and abemaciclib (VERZENIOTM, Eli Lilly and Company). This evidence concerns the gene CDK4 and breast cancer.